JRCT ID: jRCT1080222497
Registered date:27/05/2014
Basic Information
Recruitment status | |
---|---|
Health condition(s) or Problem(s) studied | Type 2 Diabetes Mellitus |
Date of first enrollment | 27/05/2014 |
Target sample size | 40 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : TS-071 INN of investigational material : luseogliflozin Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : Oral control material(s) Generic name etc : Placebo INN of investigational material : Therapeutic category code : --- Other Dosage and Administration for Investigational material : Oral |
Outcome(s)
Primary Outcome | Blood glucose(CGM) |
---|---|
Secondary Outcome | Adverse event |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | - Type 2 diabetes mellitus etc. |
Exclude criteria | - Having non-type 2 diabetes mellitus. - Having critical Heart Disease, other ciruculatory disease, cerebrovascular disorder, pancreatic disease and hematologic disease. etc. |
Related Information
Primary Sponsor | Taisho Pharmaceutical co., LTD |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | JapicCTI-142548 |
Contact
Public contact | |
Name | |
Address | Clinical-trials@so.taisho.co.jp |
Telephone | |
Affiliation | Taisho Pharmaceutical Co., Ltd |
Scientific contact | |
Name | |
Address | Clinical-trials@so.taisho.co.jp |
Telephone | |
Affiliation | Taisho Pharmaceutical Co., Ltd |